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Though bladder urothelial carcinoma is the most common form of bladder cancer, advances in its diagnosis and
treatment have been modest in the past few decades. To evaluate miRNAs as putative disease markers for bladder
urothelial carcinoma, this study develops a process to identify dysregulated miRNAs in cancer patients and
potentially stratify patients based on the association of their microRNAome phenotype to genomic alterations.
Using RNA sequencing data for 409 patients from the Cancer Genome Atlas, we examined miRNA differential
expression between cancer and normal tissues and associated differentially expressed miRNAs with patient
survival and clinical variables. We then correlated miRNA expressions with genomic alterations using the Wilcoxon
test and REVEALER. We found a panel of six miRNAs dysregulated in bladder cancer and exhibited correlations to
patient survival. We also performed differential expression analysis and clinical variable correlations to identify
miRNAs associated with tobacco smoking, the most important risk factor for bladder cancer. Two miRNAs, miR-
323a and miR-431, were differentially expressed in smoking patients compared to nonsmoking patients and were
associated with primary tumor size. Functional studies of these miRNAs and the genomic features we identified
for potential stratification may reveal underlying mechanisms of bladder cancer carcinogenesis and further
diagnosis and treatment methods for urothelial bladder carcinoma.
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ladder cancer is the ninth most common cancer worldwide,
counting for 430,000 new cases and 165,000 deaths per year [1].
ver 90% of bladder cancers are urothelial carcinoma, a transitional
ll cancer [2]. An estimated 25% of patients are diagnosed with
uscle invasive carcinoma, which has a much higher mortality rate
an nonmuscular invasive bladder cancer [2]. However, the efficacy
current diagnosis and treatment methods is under question. A
12 survey revealed that out of 4790 diagnosed patients, only one
ceived the full scope of recommended treatments, most likely
cause a comprehensive treatment is overly complex and uncom-
rtable for patients [3]. For patients who are treated for muscle
vasive cancer, poor prognosis and recurrence of tumor are common
spite radical surgery or radiation treatments [2]. The discomfort
volved in screenings for urothelial carcinoma, including upper
inary tract imaging and cystoscopy, serves as a barrier for early
agnosis of bladder cancer [3]. An understanding of the molecular
thogenesis of bladder urothelial carcinoma can increase theandard of care for patients by providing biomarkers that improve
agnosis efficiency, reduce treatment duration, and increase the
ccess rate of treatments.
MicroRNAs (miRNAs) are a class of noncoding RNAs 19 to 22
cleotides long that regulate protein-coding target genes through
NA interference and gene silencing. Because of their widespread
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at can address current needs in diagnosis and treatment. miRNAs
nd to complementary sequences of 3′-untranslated regions of
RNAs to block translation or to mark the mRNAs for degradation
]. The dysregulation of miRNA and other classes of noncoding
NAs, such as long noncoding RNAs, is implicated in the
rcinogenesis of a variety of cancers, including bladder urothelial
rcinoma, and can act as either tumor suppressors or oncogenes [5].
urrently, patients must undergo painful cystoscopy to test for the
esence of bladder carcinoma and recurrence of cancer after
eatment because of the low sensitivity of less invasive urinary
tology tests [6]. However, ribonucleotides are stable and detectable
body fluids such as urine, and most circulating RNAs are reported
be miRNAs or long noncoding RNAs, as opposed to mRNAs,
aking miRNA potential diagnostic markers.
A number of studies have previously identified specific miRNAs
regulated or downregulated in bladder cancer [5,7]. However,
ese studies are often severely limited by the number of patients
volved. Most examined dysregulation of individual miRNAs in
olation from other dysregulated RNAs, with an inconsistent method
analysis employed for the individual studies [5]. To perform a more
mprehensive analysis of miRNA dysregulation, we utilized RNA-
quencing data of bladder urothelial carcinoma samples from 409
tients available from The Cancer Genome Atlas (TCGA) database.
panel of six dysregulated miRNAs was identified to be differentially
pressed and statistically associated with patient survival rates. These
nes were further tested for association with clinical variables,
utations, and copy number variations (CNVs) to assess their clinical
gnificance. Finally, we utilized an information theory-based
oinformatics tool to perform more rigorous correlations of
iRNA expressions with genomic alterations. Besides providing
tential insights into the genomic elements responsible for miRNA
sregulation, these correlations can allow for the stratification of
tients into groups with similar genomic profiles through miRNA
pressions to aid with diagnosis and treatment. Because tobacco
oking is a major risk factor for bladder cancer, we also examined
iRNA dysregulation in smokers compared to nonsmokers so that
iology may be factored into a comprehensive miRNA panel for
aracterizing bladder cancer.
aterial and Methods
iRNA-Sequencing Datasets and Clinical Data
Level 3–normalized miRNA expression datasets and clinical data
r 409 bladder urothelial carcinoma patients were obtained on 17
pril 2017 from TCGA (https://tcga-data.nci.nih.gov/tcga). Datasets
om 19 solid normal tissue samples of bladder urothelial patients
ere also obtained. All cases were muscle invasive urothelial
rcinoma. Most samples (306 patients) were obtained using
ansurethral resection. Forty-six samples were obtained through
doscopic biopsy. Other samples were obtained through cystectomy
cystoprostatectomy. No patients received chemotherapy or
diation therapy prior to sample collection. After sample collection,
patients were treated with radiation therapy, and 114 patients
ceived chemotherapy. One hundred and nine patients died at the
me of data upload. Eleven patients had distant metastasis. Patients
ere followed until death or to a maximum of 4684 days in this
CGA study. We separated patients into two pairs of cohorts: cancer
d normal cohorts as well as smoker and nonsmoker cohorts.iRNA Differential Expression Analyses
MiRNA read counts were extracted from the TCGA Level 3 gene
pression files. The read count tables were imported into edgeR v3.5
ttp://www.bioconductor.org/packages/release/bioc/html/edgeR.html),
d lowly expressed miRNAs (counts per million b1 in more than the
mber of samples in the smaller cohort) were filtered from the analysis.
llowing TMM (trimmed mean of M-values) normalization, pairwise
signs were applied to identify significantly differentially expressed
iRNAs in 1) bladder urothelial carcinoma tumor tissues versus normal
sues and 2) tumor tissues from lifelong nonsmoking patients versus
mor tissues from patients with history of smoking. All miRNAs
entified as differentially expressed in each edgeR comparison were
tained as candidates.
ssociation of Candidate miRNAs with Patient Survival and
linical Variables
Survival analyses were performed using the Kaplan-Meier model,
ith miRNA expression in bladder urothelial carcinoma tumors
signated as a binary variable based on expression above or below
e median. The time to censoring or event was designated as days
last follow-up or days to death, respectively. Univariate Cox
gression analysis was used to identify candidates significantly
sociated with patient survival (P b .05). Survival-correlated
iRNAs between cancer and normal cohorts were evaluated for
inical significance. Employing the Kruskal-Wallis test, we
vestigated miRNA association with neoplasm grade, pathologic
ages, and nodal extracapsular spread using clinical data and miRNA
pression values (counts per million) from bladder urothelial
rcinoma patients. The UICC/AJCCTNM staging systemwas used
r pathological stages. In pathological T stage analysis, patients with
ages T1a and T1b were grouped into stage T1, and likewise for
ages T2, T3, and T4. Patients with no available information for a
ven characteristic were filtered from analyses involving that
riable. Multivariate Cox analysis was then performed to evaluate
hether correlations were independent of clinical variables such
smoking history, gender, pathological stages, and presence of
mphovascular invasion.
ssociation of Candidate Survival-RelatedmiRNAs with Common
enomic Alterations
Mutation and CNV data for the bladder urothelial carcinoma
mors were obtained from mutation and CNV annotation files
nerated by the Broad Institute GDAC Firehose on 16 May 2017.
e focused our analysis on the 26 most frequently mutated genes in
othelial bladder carcinoma and 39 loci of frequent CNV, as
termined by Weistein et al. [7]. Wilcoxon rank sum tests were
ployed to test for significant associations between miRNA
pression level (counts per million) and mutational and CNV status.
formation-Coefficient–Based Correlation of miRNA Expression
ith Genomic Alterations
The annotation files for mutation and CNVs were compiled into a
nary input file for the program REVEALER (repeated evaluation of
riables conditional entropy and redundancy), designed to compu-
tional identify a set of specific CNVs and mutations most likely
sponsible for the change in activity of a target profile [8]. The target
ofile was defined in our study to be miRNA expression. In order to
entify a set of most relevant genomic alterations, REVEALER runs
ultiple iterations of the correlation algorithm, with the genomic
ature exhibiting the strongest correlation in each run serving as a
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Figure 1. Summary of differential expression results. (A) Heatmap of significantly dysregulated miRNAs (FDRb 0.05) in normal tissues (n=
19) versus in bladder urothelial carcinoma tissues (n=409). Low expression is represented by solid green; dark green to black represents
medium expression; dark red to solid red represents higher expression. (B) Circular representation (Circos Plot) of miRNA differential
expression between normal tissue cohort (inner ring) and cancer tissue cohort (outer ring). Each red bar represents the averaged
expression within a cohort of a particular miRNA, arranged according to its position within the genome.
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three. A seed is a particular mutation or copy number gain or loss
ent that most likely accounts for the target activity. When given a
ed, REVEALER will focus correlation on only patients with altered
rget activity not accounted for by the seed. Since we do not know
hich genomic alteration is responsible for the dysregulation of each
iRNA, we set the seed for the first iteration to null. We set the
reshold of genomic features to input to features present in less than
% of all samples.
esults
entifying DysregulatedmiRNA in Bladder Urothelial Carcinoma
To determine the extent of miRNA dysregulation in bladder
othelial cancer patients, miRNA read-counts data of cancer genomes
om 409 patients were downloaded from TCGA. These miRNA
pression data were compared against the miRNA read counts of 19
rmal tissue genomes, with each normal sample paired with a cancer
mple from the above 409 patients. After performing differential
pression analysis using the negative-binomial model, 236 miRNAs
ere identified to be differentially expressed in cancer tissue compared
normal tissue (P b .05; Figure 1). The P value was corrected for
ultiple hypothesis testing using the Bonferroni method. We focused
r analysis on 218 miRNAs that had a fold change greater than 2 and
DR b 0.0005.
A large number of previously identified dysregulated miRNAs
bladder carcinoma were confirmed to be differentially expressed
our analysis, including miR-1 [9], miR-96 [10], mir-143 [11],
iR-133a [9], mir-490 [12], mir-195 [13], and miR-99a [14], in
der of decreasing fold change. All of the above miRNAs showedeater than four-fold difference in our analysis, and their
sregulation (upregulation or downregulation) corresponded with
eviously published results. However, most dysregulated miRNAs
e identified have not been shown to be associated with bladder
ncer in published literature.
ssessing the Correlation of Dysregulated miRNA with Patient
urvival
The expression levels of the 218 candidate miRNAs were analyzed
r correlation with patient survival using the Kaplan-Meier estimate
odel. The Kaplan-Meier method uses right-censored observations
account for patients that have yet to reach the outcome of interest,
hich is death in survival analysis, at the time of data collection.
xpression levels of the candidate miRNAs were divided into high
d low expressions at the median expression level, and a Kaplan-
eier regression curve was plotted for each level (Figure 2). The Cox
oportional-hazards regression model was applied to determine
hether the differential survival rate for the two curves was
atistically significant. The expression levels of 44 miRNAs were
und to have significant correlation with patient survival rates
b.05). Six miRNAs exhibited correlation with patient survival
nsistent with the direction of dysregulation (i.e., high expression of
regulated miRNAs in bladder cancer samples corresponded with
orer survival prognosis, while low expression of downregulated
iRNAs corresponded with poorer prognosis) (Table 1). The
regulation of four miRNAs, miR-483, miR-33b, miR-33a, and
iR-3065, correlated with lower patient survival rates, suggesting the
tential oncogenic roles of these miRNAs. The downregulation of
o miRNAs, miR-378c and miR-30e, correlated with lower patient
rvival rates, suggesting tumor-suppressing roles. All six miRNAs
ha
st
ha
ca
C
w
va
gr
W
(P
co
su
an
gr
su
an
ti
m
in
ge
Su
A
A
el
ge
ur
of
ge
W
ex
w
w
in
m
3p
an
w
(F
pa
m
th
co
Mir-33a Expression Correlation with Survival
High Expression
Low Expression
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Pr
op
or
tio
n 
Su
rv
ivi
ng
0 500 1000 1500 2000 2500 3000
Time (days)
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Pr
op
or
tio
n 
Su
rv
ivi
ng
0 500 1000 1500 2000 2500 3000
Time (days)
Mir-483 Expression Correlation with Survival
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Pr
op
or
tio
n 
Su
rv
ivi
ng
0 500 1000 1500 2000 2500 3000
Time (days)
Mir-378c Expression Correlation with Survival
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Pr
op
or
tio
n 
Su
rv
ivi
ng
0 500 1000 1500 2000 2500 3000
Time (days)
Mir-33b Expression Correlation with Survival
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Pr
op
or
tio
n 
Su
rv
ivi
ng
0 500 1000 1500 2000 2500 3000
Time (days)
Mir-30e Expression Correlation with Survival
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Pr
op
or
tio
n 
Su
rv
ivi
ng
0 500 1000 1500 2000 2500 3000
Time (days)
Mir-3065 Expression Correlation with Survival
High Expression
Low Expression
High Expression
Low Expression
High Expression
Low Expression
High Expression
Low Expression
High Expression
Low Expression
p= 0.022p= 0.030
p= 0.020p= 0.041
p= 0.025
p= 0.016
n=205
n=204
Figure 2. Kaplan-Meier survival plots depicting survival outcomes of bladder urothelial carcinoma patients associated with six
differentially expressed miRNAs. The two curves in each plot denote high and low miRNA expression, respectively.
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udies. However, with the exception of miR-483, these miRNAs
ve well-documented correlations with the development of other
ncers.
orrelating miRNA Expression Levels with Clinical Variables
The six dysregulated miRNAs identified in patient survival analysis
ere analyzed for any relationship between their expression and
rious clinical variables, including pathological stage, neoplasm
ade, and primary tumor size (pathological T stage). The Kruskal-
allis test was used to determine the significance of correlation
b.05). Higher miR-33a and miR-33b expression levels were
rrelated with a greater extent of metastasis, which further
ggested their oncogenic role (Figure 3, A and B). Lower miR-30e
d miR-378c expression levels were correlated with higher tumor
ade, higher pathological stage, and greater primary tumor size,
ggesting a tumor-suppressing role for these miRNAs (Figure 3, C
d D).
Multivariate Cox regression analysis revealed that the associa-
on of miR-30e downregulation and miR-33a, miR-33b, and
iR-483 upregulation with poor patient outcome was largely
dependent of clinical prognostic factors such as smoking history,
nder, clinical stages, and lymphovascular invasion (Pb.05;
pp. Table 1).ssociating miRNA Expression Levels with Common Genomic
lterations in Bladder Urothelial Carcinoma
The potential function of the survival-correlated miRNAs could be
ucidated by associating their expression levels to changes in the
nome that can drive the pathogenesis and progression of bladder
othelial carcinoma, such as CNV or mutational changes.
Somatic CNVs can be associated with the activation or inactivation
miRNAs in cancers, with a large fraction of miRNAs located within
nomic sites that undergo frequent copy number gains or losses [15].
e focused on analyzing correlation of survival-related miRNA
pressions with CNVs of 39 loci of the genome where high CNV
as previously found in bladder cancer [7]. TheWilcoxon rank sum test
as applied to determine the significance of correlation (Pb.05). CNVs
32 unique loci correlated with miRNA expression levels, with the
ost significant correlations caused by the deletion of 2q22.1 and
14.2, which correlated with dysregulation of miR-33a, miR-33b,
d miR-30e (Figure 4, A-C). The amplification of 3q26.2 correlated
ith the increased expression of miR-33a, mR-33b, and miR-3065
igure 4, B-D). Other significant correlations were shown in Figure 4.
A number of mutations have shown to be actively involved in the
thogenesis of bladder cancer, although the underlying molecular
echanism of cancer-related pathways is poorly understood and
ought to be more complex than previously conceived. The most
mmon mutations associated with bladder urothelial carcinoma,
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Table 1. List of miRNAs with Significant Differential Expression between Cancer and Normal
Samples and Significant Correlation with Patient Survival
Fold Change P Value FDR
miR-483 22.26 2.8E-03 1.8E-05
miR-33b 6.76 5.2E-06 6.4E-08
miR-33a 5.51 1.5E-09 3.0E-11
miR-3065 3.58 9.0E-03 4.8E-05
miR-378c 0.39 4.5E-07 6.9E-09
miR-30e 0.49 5.7E-10 1.3E-11
Fi
le
co
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ere the focus of our analysis [8]. Using the Wilcoxon rank sum test
b.05), we found that the downregulation of miR-30e and miR-
8c, the two miRNAs found to be downregulated in bladder cancer
ssues in our analysis, correlated with the presence of TP53 mutation
igure 5, A and C). TP53 has been identified as a target of the miR-
family as well as associated to miR-30e in other cancers, but the
echanism of miR-30e interaction with TP53 has yet to be explored
6]. Additionally, the presence of mutations in RHOA was associated
ith elevated expression of miR-30e and lowered expression of miR-
b, while presence of mutations in FGFR3 was associated with
evated expressions of miR-30e and miR-378c (Figure 5).
entification of Dysregulated miRNAs Implicated in Smoking
d Correlation with Clinical Variables
Since tobacco smoking is the most widely established risk factor in
adder cancer, we attempted to correlate miRNA dysregulation with
tient smoking status to explore the potential mechanisms of bladder
ncer pathogenesis due to smoking. Differential expression analysis
as performed on smokers’ cancer tissues versus lifelong nonsmokers’No Yes
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gure 3. Correlation of candidate miRNAs with clinical varibales. (A-B
vels of survival-associated miRNAs (A) miR-33a and (B) miR-33b and
rrelation of (C) miR-30e and (D) miR-378c expression levels with neoncer tissues (Figure 6A). The six survival-correlated miRNAs
entified above were not implicated with smoking in the differential
pression analysis results. Twenty-nine miRNAs were identified to
differentially expressed between smokers and nonsmokers (Pb.05
d FDRb0.05). Twenty-one miRNAs with fold change greater than
o were selected for correlations with clinical variables (Table 2).
iR-431 and miR-323a appeared to be upregulated in cancer tissues
smokers versus that of nonsmokers, and their increased expressions
rrelated with increased primary tumor size, suggesting an oncogenic
le for these miRNAs (Figure 6B). Increased miR-431 expression
so correlated with increased tumor invasion of surrounding lymph
d vascular tissues (Figure 6B).
omputational Correlations for Comprehensive Analysis of All
nown Bladder Urothelial Carcinoma Genomic Alterations’
ssociation with miRNA Expression
The REVEALER algorithm, developed by Kim et al., was used to
mputational correlate all genomic alterations present in bladder
ncer samples to miRNA expression [8]. This exhaustive process
ms to identify genomic alternations that are functionally responsible
r the range of miRNA expression values in the patient samples, as
posed to associations with the general potential driving processes of
adder cancer that we performed in a previous analysis. Utilizing the
ncepts of mutual information and information coefficient from the
formation theory, REVEALER calculates a conditional information
efficient (CIC) for each genomic alteration event. When the
solute value of the CIC is around 0.30 or above, the correlation
tween the event and miRNA expression is reasonably established,
sed on simulated test data sets [8]. The most significant correlations
e displayed in Figure 7.T0 T1 T2 T3 T4
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Figure 4. Boxplots depicting significant correlations of survival-associated miRNAs’ expressions with CNV. CNVs of loci 3p14.2, 2q34,
and 2q22.1 were significantly associated with the expression of (A) miR-30e, (B) miR-33a, and (C) miR-33b. CNV of locus 3q26.2 was
associated with the expression of (B) miR-33a, (C) miR-33b, and (D) miR-3065. Significant associations with CNVs of other loci were seen
for (E) miR-378c expression. Samples with expression values greater than three times the interquartile range above the median were
considered outliers and not displayed.
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oncoding RNAs, including miRNAs, are known to be involved in
ncer pathogenesis pathways. The mechanisms of action of miRNA
e relatively well studied and characterized relative to other
ncoding RNAs such as long noncoding RNAs, making miRNAs
omising candidates to serve as potential disease markers [5]. New
omarkers for diagnostic purposes and for prognostic prediction are
gently needed for bladder cancer since, currently, there are no
omarkers that have adequate sensitivity or specificity, and no new
eatment method has been approved for more than 30 years.
owever, since the pathogenesis and molecular mechanisms of
adder cancer have been extensively documented, investigating
gulatory molecules such as noncoding RNAs and their association
ith known mechanisms in bladder cancer initiation or development
ay yield insights into their clinical significance and function.
We identified 236 miRNAs to be differentially expressed in a
tient cohort of 409 bladder urothelial carcinoma patients
DRb0.05). Out of these candidates, six miRNAs, miR-483,
iR-33b, miR-33a, miR-3065, miR-378c and miR-30e, correlatedith patient survival through univariate Cox regression analysis
b.05). miR-378c and miR-30e were downregulated in cancer
tients, while the other four miRNAs were upregulated. To the best
our knowledge, none of these miRNAs were previously found to be
plicated in bladder cancer. Multivariate Cox regression analysis was
rformed on pathological staging, smoking history, lymphovascular
vasion, and gender for these six miRNAs. The correlation between
pression and poor prognosis was independent of the above variables
r miR-30e, miR-33a, miR-33b, and miR-483.
The survival-correlated miRNAs were associated with somatic
NVs in 32 loci. CNV of locus 2q22.1, the site of LRP1B and
equently deleted in bladder cancer [7], was strongly implicated with
e upregulation of miR-33a, miR-33b, and miR-30e (Pb.003,
ilcoxon rank sum). LRP1B, an LDL receptor-related protein, is
ell known as a tumor suppressor across multiple cancers. LRP1B
as found to be a target of miR-30e in broiler chickens, but no
sociation between LRP1B and miR-33a, miR-33b, or miR-30e has
en find in humans [17]. CNV of locus 3p14.2, containing the gene
IT and also frequently deleted in bladder cancer [7], was associated
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Figure 5. Mutational correlations using Wilcoxon rank sum. Boxplots depicting significant correlations of the expressions of survival-
correlated miRNAs (A) miR-30e, (B) miR-378c, and (C) miR-33b with mutation status of commonly mutated genes in bladder urothelial
carcinoma, including FGFR3, TP53, and RHOA.
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d miR-33b in our analysis. FHIT is a known tumor suppressor that
as found to mediate the increased expression of miR-30c, from the
me family as miR-30e, in lung cancer to suppress genes that
omote metastasis [18].
The expression levels of the six survival-related miRNAs were
sociated with presence of mutations in the genes TP53, RHOA, and
GFR3. Forty-nine percent of bladder urothelial carcinoma patients
ve a mutation in TP53 [7], a well-studied tumor suppressor gene
at is known to have a complex interaction with miRNAs and is both
regulator of miRNA expression and target of miRNAs. The presence
mutation in TP53 correlated with the downregulation of miR-30e
d miR-378c, both of which are expected to have tumor suppressive
les in bladder cancer from our differential expression analysis data.
udies in colon carcinoma have suggested that miR-30e increases the
pression of the tumor suppressor protein p21 that is downstream of
P53 [19]. The TP53-p21 pathway was also found to be implicated
ith miR-378c [20]. The presence of mutation in RHOA correlated
ith the upregulation of miR-30e and the downregulation of miR-
b. RHOA appears to have an oncogenic role in bladder urothelial
rcinoma, and the expression of miR-33b was reported to activate
HOA in melanoma cells [21,22]. FGFR3 is also frequently reported
be mutated in bladder cancer, with 12% of a sample of over 400
tients possessing a mutation of this gene [7]. Mutation in FGFR3
as correlated with the upregulation of miR-30e, miR-378c, and
iR-483 in our analysis, but no studies have linked these miRNAs to
GFR3. Collectively, these findings suggest the possibility of using
ngle or a combination of miRNAs to detect genomic alterations in
adder cancer, underscoring the importance of further investigating
e underlying mechanisms of genes within these genomic regions in
gulating miRNAs to better understand their roles in bladder
othelial carcinoma carcinogenesis.
Because smoking is a major risk factor of bladder cancer, we
rrelated miRNA expression to smoking history to explore the effects
smoking on miRNA dysregulation and how this relationship can
tentially contribute to oncogenesis. miR-431 and miR-323a weregnificantly upregulated in smoking patients’ tumor tissues com-
red to nonsmoking patients’. Their upregulation also correlated
ith increased primary tumor size (pathological T stage). The
plication of smoking in the dysregulation of miRNAs has been
udied in lung cancer but not bladder cancer, to our best knowledge
3]. miR-323a was reported to be upregulated in smoker versus
nsmoker lung cancer patient cohorts, consistent with our results in
adder cancer [24]. miR-431 was reported to be dysregulated in the
ng cells of mice exposed to smoke, although it was identified as
ving a tumor suppressing role [25]. As in lung cancer, miRNAs may
ay a role in the carcinogenesis of bladder cancer as well through their
teraction with carcinogens in cigarette smoke.
We next used the REVEALER program to perform a more
mprehensive correlation of miRNA expression with genomic
terations beyond those that are most common and previously
termined to be associated with bladder cancer. The landscape of
NVs and mutations revealed to have significant association with
iRNA expression by REVEALER is very different from the
sociations observed from correlations using the Wilcoxon rank
m test. With the exception of FGFR3 mutation, no mutations
ared the threshold of 0.30 for significant correlation, and many
wer CNVs exhibiting significant correlation with each miRNA
pression were observed with REVEALER compared to that
served with the Wilcoxon test. These results suggested that
EVEALER may be more selective and statistically robust than the
ilcoxon test. However, differences in the statistical approach discourage
e assumption that REVEALER is always more conservative in its
rrelations. For example, FGFR3 mutation is less strongly associated
ith the dysregulation of miR-483 than the dysregulation of miR-30e
d miR-378c according to theWilcoxon P value, but FGFR3mutation
more significantly associated with miR-483 dysregulation according to
e REVEALER conditional information coefficient, while association of
FR3 mutation with miR-30e and miR-378c dysregulation was not
ar the significant threshold of 0.30. This outcome suggested that both
ethods may be of value when determining associations of miRNA
pression with genomic features.
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Figure 6. Candidate miRNAs associated with tobacco smoking. (A) Heatmap of miRNA expression (in counts per million) of cancer
samples from nonsmoking patients compared to that of cancer samples from smoking patients. In order from low expression to high
expression, the heatmap colors are green, dark green, black, dark red, and red. (B) Boxplots depicting correlations between the
expressions of smoking-associated miRNAs miR-323a and miR-431 and pathological T stage and lymphovascular invasion.
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teration with the strongest correlations as a seed for subsequent
erations and then penalizing the CIC for genomic alterations present
patients who also possess the seed alteration, with the reasoning
at the dysregulation of miRNA in those patients would be better
counted for by the seed [8]. This approach can lead to the discoveryab
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ble 2. List of miRNAs with Significant Differential Expression between Cancer Samples from
okers and Nonsmokers
Fold Change P Value FDR
R-527 6.50 3.4E-05 4.2E-06
R-518a-2 5.66 1.9E-04 1.9E-05
R-518c 5.60 1.7E-04 1.8E-05
R-518e 4.79 1.4E-03 1.1E-04
R-525 4.45 3.9E-03 2.6E-04
iR-517a 4.10 8.9E-03 4.8E-04
iR-517b 4.08 9.5E-03 4.8E-04
iR-516a-1 3.99 4.2E-04 3.8E-05
iR-520a 3.97 9.5E-03 4.8E-04
iR-194-2 0.27 3.7E-29 3.7E-29
iR-526b 3.67 6.8E-03 4.0E-04
iR-194-1 0.28 1.7E-27 8.4E-28
iR-516a-2 3.60 1.8E-03 1.3E-04
iR-518b 3.55 2.0E-02 8.5E-04
iR-522 3.34 2.9E-02 1.1E-03
iR-519a-2 3.33 1.7E-02 7.7E-04
iR-217 3.28 4.2E-06 7.0E-07
iR-215 0.32 3.7E-06 7.0E-07
iR-431 2.72 2.6E-07 6.5E-08
iR-192 0.39 3.2E-13 1.1E-13
iR-323a 2.51 1.2E-05 1.8E-06genomic alterations that may account for a portion of
sregulations but were not recognized as significant by traditional
proaches such as the Wilcoxon test because of the researcher’s
terest in stronger correlations exhibited by other genomic
terations. More importantly, this innovative feature of REVEALER
lows for the stratification of patients based on their genomic
normalities using miRNAs as a biomarker.
The heterogenous nature of tumors across different patients
cessitates the need for identification of specific patient cohorts that
spond differently to treatment but prohibits the easy detection of
ch clinically relevant tumor subtypes. Mutations and somatic
NVs are genomic alterations critical to the mechanism of cancer
velopment [26,27], and we hope the dissection of their
terogeneity within cancers may lead to informative stratifications
patients. Great advancements have been made in developing
ethods to determine which CNVs and mutations are functionally
levant in the initiation and progression of cancers [28-29], but the
e of biomarkers to stratify patients based on these critical CNVs and
utations was less well studied. Most studies on bladder cancer
omarkers focused on identification of the tumor itself instead of
mor stratification. To illustrate, by testing for a panel of three
iRNAs (miR-15b, miR-135b, and miR-1224-3p) isolated from
ine samples, the sensitivity for diagnosing bladder cancer was found
be 94%, but the specificity was only 51% [30]. Because of the high
terogeneity in clinical characteristics of individual diagnoses,
equate specificity in diagnosing bladder cancer using miRNAs as
omarkers remains a challenge. Stratification of tumors during
agnosis, using personalized diagnosis methods that link the presence
of
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Figure 7. Association of genomic alterations with miRNA expression using REVEALER. The gradient bar visualizes the expression
distribution of miRNAs. The dark red extreme represents the highest expression, while the dark blue extreme represents the lowest
expression. Genomic alterations are analyzed for correlation with low miRNA expression in (A) downregulated miRNAs, while they are
analyzed for correlation with high miRNA expression in (B) upregulated miRNAs. Thus, the CIC is negative for correlations with miR-30e
and miR-378c expressions. Significant correlation can be visually examined by the increased density of dark blue vertical bars to the
extreme left of each row compared to the extreme right. Each vertical bar represents the presence of the stated genomic feature in a
specific patient. However, care must be taken when asserting correlations based on visual inspection because of the nonlinear
distribution of expression values in each plot. Significant correlation was determined with CIC of around 0.30 or higher. A red dividing bar
in between genomic features signifies a change in iteration. Results from iterations yielding no significant correlations are not displayed.
372 Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker Li et al.Neoplasia Vol. 20, No. 4, 2018specific miRNAs to specific mechanisms of bladder cancer
thogenesis rather than using miRNA presence as a general marker
bladder cancer presence, may improve diagnostic accuracy. Our
udy demonstrates a workflow that allows for the specific
entification of potentially valuable miRNAs for use as biomarkers
d the specific CNVs and mutations they may be able to detect.
Supplementary data to this article can be found online at https://
i.org/10.1016/j.neo.2018.01.008.
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